BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 30536809)

  • 1. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
    Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.
    Chen SC; Huang HP; Huang WS; Lin YC; Chu TP; Beaton RD; Jane SW
    Eur J Oncol Nurs; 2020 Dec; 49():101834. PubMed ID: 33120223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
    Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
    J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
    Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Briani C; Argyriou AA; Izquierdo C; Velasco R; Campagnolo M; Alberti P; Frigeni B; Cacciavillani M; Bergamo F; Cortinovis D; Cazzaniga M; Bruna J; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2014 Dec; 19(4):299-306. PubMed ID: 25582667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.
    Argyriou AA; Cavaletti G; Antonacopoulou A; Genazzani AA; Briani C; Bruna J; Terrazzino S; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Psaromyalou A; Angelopoulou A; Kalofonos HP
    Cancer; 2013 Oct; 119(19):3570-7. PubMed ID: 23821303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
    Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
    Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
    Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.
    Argyriou AA; Briani C; Cavaletti G; Bruna J; Alberti P; Velasco R; Lonardi S; Cortinovis D; Cazzaniga M; Campagnolo M; Santos C; Kalofonos HP
    Eur J Neurol; 2013 May; 20(5):788-94. PubMed ID: 23252594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity.
    Argyriou AA; Antonacopoulou AG; Alberti P; Briani C; Bruna J; Velasco R; Anastopoulou GG; Park SB; Cavaletti G; Kalofonos HP
    J Peripher Nerv Syst; 2019 Dec; 24(4):298-303. PubMed ID: 31486252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphisms in cyclin H gene are associated with oxaliplatin-induced acute peripheral neuropathy in South Indian digestive tract cancer patients.
    Palugulla S; Devaraju P; Kayal S; Narayan SK; Mathaiyan J
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):421-428. PubMed ID: 29936608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.
    Terrazzino S; Argyriou AA; Cargnin S; Antonacopoulou AG; Briani C; Bruna J; Velasco R; Alberti P; Campagnolo M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP; Canonico PL; Genazzani AA; Cavaletti G
    J Peripher Nerv Syst; 2015 Mar; 20(1):15-23. PubMed ID: 25858589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
    Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
    Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer.
    Nagata T; Fukuda KI; Tamai M; Taniguchi A; Kamiya H; Kambe K; Kamada Y; Iwata G; Yamaoka N
    Anticancer Res; 2019 Mar; 39(3):1347-1353. PubMed ID: 30842168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation.
    Matsumoto Y; Yoshida Y; Kiba S; Yamashiro S; Nogami H; Ohashi N; Kajitani R; Munechika T; Nagano H; Komono A; Aisu N; Yoshimatsu G; Hasegawa S
    Support Care Cancer; 2020 Nov; 28(11):5405-5410. PubMed ID: 32144582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
    Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
    Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients.
    Palugulla S; Dkhar SA; Kayal S; Narayan SK
    Indian J Med Paediatr Oncol; 2017; 38(4):502-507. PubMed ID: 29333020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
    Tofthagen C; McAllister RD; McMillan SC
    Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.